Search

Stanton F Mchardy

from Helotes, TX
Age ~56
Get Report
Also known as:
Stanton Diana Mchardy, Stanton Melanie Mchardy, Stabton F Mchardy, Stanton Mc Hardy, Stan Mchardy, Mc Stanton
Phone and address:
19556 Nottingham Ln, Grey Forest, TX 78023
(210) 695-8987
Related to:
Dylan MchardyCynthia Mercado, 66Michelle Byrnes, 49Erin Mull, 50Melissa D Fowler, 44Lynda Fowler, 63
Connected to:
Dylan Mchardy, 47Grace M Mchardy, 80Marsha Mchardy, 50Ralph P Mchardy, 77Sean Mchardy, 63Susan A Mchardy, 65Melissa A Mcharg, 49Sarah M Mcharg, 74Bradford L Mchargue, 73Candice E Mchargue, 40

Stanton Mchardy Phones & Addresses

  • 19556 Nottingham Ln, Helotes, TX 78023 (210) 695-8987
  • San Antonio, TX
  • Waring, TX
  • Boerne, TX
  • Kendalia, TX
  • Coventry, RI
  • Norwich, CT
  • Salt Lake City, UT
  • PO Box 198, Waring, TX 78074 (210) 695-8987

Resumes

Resumes

Stanton Mchardy Photo 1

Director-Center For Innovation In Drug Discovery

View page
Location:
P/O Box 1468, Helotes, TX
Industry:
Pharmaceuticals
Work:
The University of Texas at San Antonio
Director-Center For Innovation In Drug Discovery
Southwest Research Institute Oct 2011 - Jun 2012
Assistant Director-R and D
Southwest Research Institute Aug 2008 - Oct 2011
Manager-R and D
Southwest Research Institute Oct 2007 - Aug 2008
Principal Scientist
Southwest Research Institute Jun 2006 - Oct 2007
Senior Research Scientist
Education:
University of Utah 1990 - 1996
Doctorates, Doctor of Philosophy, Chemistry Texas Lutheran University 1986 - 1990
Bachelors, Bachelor of Science, Chemistry
Skills:
Drug Discovery
Medicinal Chemistry
Organic Synthesis
Adme
Stanton Mchardy Photo 2

Stanton Mchardy

View page

Publications

Us Patents

2-Azabicyclo[3.3.1]Nonane Derivatives

View page
US Patent:
RE40838, Jul 7, 2009
Filed:
Oct 18, 2007
Appl. No.:
11/874253
Inventors:
Jotham W. Coe - Niantic CT, US
Stanton F. McHardy - Helotes TX, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A61K 31/439
C07D 221/22
US Classification:
514299, 546112
Abstract:
The subject invention relates to 2-azabicyclo[3. 3. 1]nonane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia and eating disorders, among others, as are more fully described herein.

Tetralines Antagonists Of The H-3 Receptor

View page
US Patent:
20090163482, Jun 25, 2009
Filed:
Mar 1, 2007
Appl. No.:
12/282545
Inventors:
Stanton Furst McHardy - Helotes TX, US
Vinod Dipak Parikh - Mystic CT, US
International Classification:
A61K 31/541
C07D 295/14
A61K 31/40
C07D 417/12
A61P 11/00
US Classification:
5142278, 548577, 514429, 544 60
Abstract:
This invention is directed to a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of formula (I) a process of en preparation of a compound of formula (I), a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula (I) as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula (I) as described above.

Diaryl Compounds And Uses Thereof

View page
US Patent:
20100035873, Feb 11, 2010
Filed:
Jun 23, 2009
Appl. No.:
12/489902
Inventors:
Patrick Verhoest - Old Lyme CT, US
Matthew Merrill Hayward - Old Lyme CT, US
Vinod Parikh - Mystic CT, US
Stanton Furst McHardy - Helotes TX, US
Stafford McLean - Stonington CT, US
International Classification:
A61K 31/535
C07D 401/02
A61K 31/4439
C07D 265/30
US Classification:
5142312, 5462764, 514343, 544106
Abstract:
The invention relates to derivatives of a compound of formula I:wherein Rto Rand Xto Xare as defined herein.The invention relates to the uses thereof for treating diseases, conditions and/or disorders mediated by kappa opioid receptors (KORs). Specifically, the compounds are selective antagonists of KORs and are highly selective to KORs relative to mu and delta opioid receptors.

Single Phenothiazine Enantiomers As Agents For The Prevention Of Bone Loss

View page
US Patent:
20100285087, Nov 11, 2010
Filed:
Feb 1, 2010
Appl. No.:
12/697512
Inventors:
Joseph McDonough - Helotes TX, US
Stanton Furst McHardy - Helotes TX, US
Assignee:
The University Of Texas - San Antonio TX
International Classification:
A61K 31/542
C07D 279/26
A61K 31/5415
C07D 279/22
C07D 513/04
A61F 2/28
A61K 9/70
A61P 19/04
US Classification:
424423, 544 41, 5142262, 5142258, 544 38, 5142248, 544 34, 5142245, 424449
Abstract:
Enantomerically purified phenothiazines are provided as active ingredients of medicaments to limit activity of bone resorbing cells so as to reduce bone loss. Novel phenothiazine derivatives are provided. A method of synthesizing enantiomerically pure phenothiazine derivatives is provided that avoids post-synthetic enantiomeric resolution.

Oximes For Treatment Of Peripheral And Central Nervous System Exposure To Acetyl Cholinesterase Inhibitors

View page
US Patent:
20130035351, Feb 7, 2013
Filed:
Aug 3, 2011
Appl. No.:
13/197550
Inventors:
Stanton F. MCHARDY - San Antonio TX, US
Richard M. CORBETT - San Antonio TX, US
Donald M. MAXWELL - Baltimore MD, US
Michael W. TIDWELL - Lakehills TX, US
Bismarck CAMPOS - San Antonio TX, US
Christopher J. BEMBEN - San Antonio TX, US
Assignee:
SOUTHWEST RESEARCH INSTITUTE - San Antonio TX
International Classification:
A61K 31/506
A61K 31/4545
A61K 31/445
A61K 31/44
C07C 237/06
C07D 219/10
C07D 401/12
C07D 211/30
C07D 211/72
A61K 31/4375
A61K 31/164
US Classification:
514274, 514297, 514318, 514331, 514350, 514351, 514626, 544316, 546105, 546194, 546247, 546297, 564197
Abstract:
The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.

Oximes For Treatment Of Peripheral And Central Nervous System Exposure To Acetyl Cholinesterase Inhibitors

View page
US Patent:
20140066421, Mar 6, 2014
Filed:
May 17, 2012
Appl. No.:
13/474399
Inventors:
Stanton F. McHardy - San Antonio TX, US
Richard M. Corbett - San Antonio TX, US
Donald M. Maxwell - Baltimore MD, US
Michael W. Tidwell - Lakehills TX, US
Bismarck Campos - San Antonio TX, US
Christopher J. Bemben - San Antonio TX, US
Assignee:
SOUTHWEST RESEARCH INSTITUTE - San Antonio TX
International Classification:
C07D 213/64
A61K 31/506
A61K 31/473
A61K 31/472
A61K 31/4545
A61K 31/4468
A61K 31/445
A61K 31/4439
A61K 31/44
C07D 219/12
C07D 217/16
C07D 401/12
C07D 211/34
A61K 45/06
A61K 31/4427
US Classification:
5142102, 514274, 514297, 514307, 514318, 514329, 514331, 514339, 514343, 514350, 544316, 546106, 546144, 546194, 546224, 546233, 5462681, 5462764, 5462767, 546298
Abstract:
The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.

Methods And Compositions For The Treatment Of Shiga Toxicosis

View page
US Patent:
20220202747, Jun 30, 2022
Filed:
Mar 18, 2022
Appl. No.:
17/698527
Inventors:
- Austin TX, US
Stanton F. McHardy - San Antonio TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 31/138
A61K 33/32
A61P 31/04
A61K 31/4535
Abstract:
Methods for treating Shiga toxicosis, caused by infection with Shiga toxin bacteria, are provided. The methods include administering to a subject in need thereof an effective amount of one or more active agents selected from tamoxifen, 4-hydroxytamoxifen, endoxifen, toremifene, raloxifene, bazedoxifene, and pharmaceutically acceptable salts thereof. In some embodiments, the methods further include the administration of an antibiotic or a manganese compound to the subject. Pharmaceutical compositions for the treatment of Shiga toxicosis are also described.

Inhibition Of Olig2 Activity

View page
US Patent:
20210347739, Nov 11, 2021
Filed:
Jul 2, 2021
Appl. No.:
17/367099
Inventors:
- Austin TX, US
Fabio C. TUCCI - San Diego CA, US
Satheesh B. RAVULA - San Diego CA, US
Stanton F. McHARDY - Waring TX, US
Francisco Xavier RUIZ - Conroe TX, US
Ambrosio LOPEZ - San Antonio TX, US
Bismarck CAMPOS - San Antonio TX, US
Hua-Yu Leo WANG - San Antonio TX, US
International Classification:
C07D 239/48
C07D 403/12
C07D 401/14
C07D 401/12
C07D 403/04
C07D 405/12
Abstract:
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
Control profile
Stanton F Mchardy from Helotes, TX, age ~56 Get Report